by support | Nov 28, 2022 | Uncategorized
The voice of the patient has a role in the drug development and approval process. In fact, recent legislation mandates an increased emphasis on incorporating the patient perspective into the drug approval process.
by support | Nov 28, 2022 | Uncategorized
Every day, NTM Info & Research’s commitment to finding therapies serves as hope for the NTM community. We are constantly looking for ways to boost our financial support of research to achieve better treatments and, eventually, a cure. Until that cure is found, we...
by support | Nov 28, 2022 | Uncategorized
On April 8th, 2019 the U.S. Food & Drug Administration will host a public workshop on the development of antibacterial drugs for the treatment of nontuberculous mycobacterial (NTM) infection.
by support | Nov 28, 2022 | Uncategorized
The FDA workshop on “The Development of Antibiotics for the Treatment of NTM Disease” on April 8, 2019 was very successful, with more than 100 people attending in person. The agenda focused on issues surrounding clinical trials and the development of a validated...
by support | Nov 28, 2022 | Uncategorized
Dear Friends of NTM Info & Research, It is with a mixture of gratitude and sadness that I announce the retirement of Philip Leitman as President of NTM Info & Research. Philip, who co-founded NTMir with his late wife, Fern, will continue as President Emeritus...
by support | Nov 28, 2022 | Uncategorized
NTM Info & Research (NTMir), the national nonprofit organization advocating on behalf of patients with nontuberculous mycobacterial (NTM) lung disease, applauds the European Commission’s decision to grant marketing authorization for ARIKAYCE® Liposomal 590 mg...
